Xiaohua Wang is the Director of Cell Therapy Applications at Bristol Myers Squibb (BMS). He is responsible for initiating and implementing a strategic plan for future collaborations in immuno-oncology, cell therapy, and gene therapy. Xiaohua is passionate about combining engineering and biology to provide more effective, accessible, and affordable therapeutic solutions for patients. Before joining BMS, he served as director of Product Science and Process Development at Fosun Kite Biotechnology, where he fostered the technology transfer and clinical manufacture of Yescarta from the US to China. He also initiated the effort to implement optofluidic technology into single-primary-cell-based antibody discovery campaigns and cell therapy to identify superior biological candidates. Xiaohua obtained his Ph.D. in Immunology from the University of Wisconsin-Madison with Dr. Jenny Gumperz. He had his Post-doctoral training first with Dr. Dario Vignali at St. Jude Research Hospital and then with Dr. Matthew Scharff at Albert Einstein College of Medicine.
